NRAS and granular cell tumor: In this way Leonard et al. recently described a case of GCT with concomitant AML which achieved a partial sustained remission for 6 months with targeted therapy after in vitro assays demonstrated an NRAS mutation common to both the GCT and the concomitant erythroleukemia [26].